Pharma BD Deal Intelligence

Theramex / Asieris Pharmaceuticals

2026 · Licensing/Option · $250M · Pending

Asieris Pharmaceuticals granted Theramex an exclusive license to develop and commercialize CEVIRA (APL-1702) across all European countries plus Australia, New Zealand and Turkey, with Asieris retaining rights for the rest of the world. Theramex pays USD 15 million upfront and USD 11 million in near-term regulatory milestones, with additional commercial milestones and tiered royalties bringing total deal value above USD 250 million. The upfront is conditional on signing a supply agreement, successful audits of CEVIRA manufacturing sites, alignment with the upstream licensing agreement, and clarification with the European Commission on the clinical value assessment of the CEVIRA device. CEVIRA is a photodynamic drug-device combination for non-surgical, healthcare-professional-administered treatment of HPV-associated cervical precancerous lesions. Photocure, the upstream licensor, separately confirmed the agreement. NOTE: ingested at pending_review pending full enrichment.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals